OncologyEducation

Dirk Schadendorf, MD, on the phase 3 STARBOARD study: first-line encorafenib, binimetinib and pembrolizumab vs. placebo and pembrolizumab in BRAF V600–mutant melanoma. #ESMO26

Watch now: bit.ly/4BtJChb

Guillermo De Velasco, MD, PhD, on enfortumab vedotin + pembrolizumab in refractory advanced melanoma (PLUG-IN GEM 2301) and the CD137/PD-L1 bispecific FS222 in PD-1 inhibitor–resistant melanoma. #ESMO26

Watch now: bit.ly/4zdxUWD

Marcelo Negrao, MD, on updated results for first-line olomorasib + chemo-immunotherapy in KRAS G12C–mutant NSCLC from LOXO-RAS-20001 and SUNRAY-01. #ESMO26

Watch now: bit.ly/47D1IzN

David Gandara, MD, on the randomized ASTRIDE trial: serplulimab or atezolizumab + chemotherapy in US patients with extensive-stage small cell lung cancer. #ESMO26

Watch now: bit.ly/47FUfQw

Federico Cappuzzo, MD, on a phase 2 trial of OSE2101 plus docetaxel or nivolumab as second-line therapy in metastatic NSCLC after first-line chemo-immunotherapy. #ESMO26

Watch now: bit.ly/47D1tVp